IL2 and renal cell adenocarcinoma: Recent data suggest that the combination of these modalities might be the future of renal cell cancer treatment and renders high-dose interleukin-2 (Fyfe et al. 1995) treatment of no additional benefit in the current renal oncology landscape (recommendation level A) (Atkins et al. 2018; Motzer et al. 2015a, b.